Breaking News Instant updates and real-time market news.

IDXX

Idexx Laboratories

$200.85

4.01 (2.04%)

, PDCO

Patterson Companies

$22.28

0.13 (0.59%)

08:15
01/22/19
01/22
08:15
01/22/19
08:15

William Blair to hold dinner and booth tours

William Blair hosts meetings and booth tours with various management teams at the 2019 Veterinary Meeting & Expo in Orlando on January 21 and 22.

IDXX

Idexx Laboratories

$200.85

4.01 (2.04%)

PDCO

Patterson Companies

$22.28

0.13 (0.59%)

PETQ

PetIQ

$27.74

-0.3 (-1.07%)

PETX

Aratana Therapeutics

$4.41

0.27 (6.52%)

TRUP

Trupanion

$28.11

0.22 (0.79%)

ZTS

Zoetis

$84.62

0.4 (0.47%)

  • 22

    Jan

  • 01

    Feb

  • 14

    Feb

IDXX Idexx Laboratories
$200.85

4.01 (2.04%)

06/01/18
FBCO
06/01/18
NO CHANGE
Target $228
FBCO
Outperform
Idexx Laboratories price target raised to $228 from $209 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for IDEXX Laboratories to $228 from $209 and maintained an Outperform rating on the shares following a meeting with the company's CEO and CFO, citing a greater conviction in the company's long-term growth prospects. At the meeting, the analyst noted that IDEXX highlighted the company's sustainable leadership position with innovative testing capabilities, "robust" commercial strategy and innovative testing capabilities.
06/15/18
ADAM
06/15/18
NO CHANGE
Target $123
ADAM
Buy
Heska price target raised to $123 from $115 at Canaccord
After Heska (HSKA) announced after the close a contract win to supply in-clinic diagnostic equipment and supplies to Pathway Vet Alliance, Canaccord analyst Mark Massaro said management confirmed that the multi-year deal was a competitive win, mostly from Idexx (IDXX). He sees the deal positioning Heska for upside in 2019 and 2020 and raised his price target on the stock to $123 from $115. Massaro keeps a Buy rating on Heska shares.
08/01/18
PIPR
08/01/18
NO CHANGE
Target $236
PIPR
Overweight
Idexx Laboratories price target raised to $236 from $211 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target on Idexx Laboratories to $236 and kept his Overweight rating after its Q2 earnings beat and raise of FY18 organic revenue growth outlook. The analyst expects continued favorable conditions in the Companion Animal Group to benefit the stock, raising his target forward earnings price multiple to 46-times from 42-times.
11/05/18
ADAM
11/05/18
NO CHANGE
Target $250
ADAM
Buy
Idexx Laboratories price target lowered to $250 from $270 at Canaccord
Canaccord analyst Mark Massaro lowered his price target on Idexx Laboratories to $250 from $270 following its Q3 results. The analyst said the company remains the best-in-class large cap growth leader in the global animal market and reset its guidance bar as readily achievable. Massaro maintained his Buy rating on Idexx Laboratories shares.
PDCO Patterson Companies
$22.28

0.13 (0.59%)

01/17/19
UBSW
01/17/19
INITIATION
Target $23
UBSW
Neutral
Patterson Companies initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Patterson Companies with a Neutral rating and $23 price target.
01/03/19
EVER
01/03/19
UPGRADE
EVER
In Line
Patterson Companies upgraded to In Line at Evercore ISI
As previously reported, Evercore ISI upgraded Patterson Companies to In Line from Underperform. Analyst Ross Muken said recent management actions to remove credit and dividend risk have enhanced financial flexibility, and the restructuring and sales force additions likely support earnings at current levels.
01/03/19
EVER
01/03/19
UPGRADE
EVER
In Line
Patterson Companies upgraded to In Line from Underperform at Evercore ISI
12/27/18
GSCO
12/27/18
NO CHANGE
GSCO
Goldman sees potential for softer macro to weigh on U.K. dental, vet spending
Goldman Sachs analyst Nathan Rich said several recent data points, including consumer spending data and Walgreens Boots Alliance's (WBA) results, suggest a more challenging environment for U.K. consumers. Given this, he sees potential for the softer U.K. macro backdrop to weigh on spending for dental and vet services. Rich noted that Patterson (PDCO) generates the highest percentage of revenue in the U.K. among dental names he covers, at 11%, adding that Align Technology (ALGN), Henry Schein (HSIC) and Dentsply Sirona (XRAY) each have about 5% exposure on average.
PETQ PetIQ
$27.74

-0.3 (-1.07%)

08/15/18
RHCO
08/15/18
NO CHANGE
Target $40
RHCO
Buy
PetIQ price target raised to $40 from $30 at SunTrust
SunTrust analyst William Chappell raised his price target on PetIQ to $40 and kept his Buy rating after its Q2 sales beat and raised FY18 guidance. The analyst notes that the investment story for the company now hinges on the wellness center rollout and expects to hear an update on those developments in the coming months.
09/28/18
KING
09/28/18
INITIATION
Target $49
KING
Buy
PetIQ initiated with a Buy at CL King
CL King analyst David Westenberg initiated PetIQ with a Buy and $49 price target.
10/05/18
OPCO
10/05/18
NO CHANGE
Target $50
OPCO
Outperform
PetIQ price target raised to $50 from $28 at Oppenheimer
Oppenheimer analyst Brian Nagel reiterated an Outperform rating on PetIQ and raised his price target to $50 from $28. In a research note to investors, Nagel says PetIQ's "unique" business model continues to take shape well and the market is still meaningfully under-appreciating the company's longer-term sales and profit potential. He also contends that the acquisition of VIP Petcare not only affords the chain a new, higher margin revenue stream, but also serves to meaningfully strengthen its core distribution business.
11/14/18
JEFF
11/14/18
NO CHANGE
Target $42
JEFF
Buy
PetIQ price target raised to $42 from $37 at Jefferies
Jefferies analyst Kevin Grundy raised his price target for PetIQ to $42 and says the stock remains a top small cap idea following its "strong" Q3 results. The company printed 5% sales upside driven by strength in its distributed portfolio, which drove an upward revision to its fiscal 2018 sales outlook, Grundy tells investors in a post-earnings research note. He adds that while EBITDA was modestly below consensus, PetIQ's outlook was reaffirmed. The analyst believes the company offers investors a "nique opportunity to participate in the high growth pet space." Grundy keeps a Buy rating on the shares.
PETX Aratana Therapeutics
$4.41

0.27 (6.52%)

03/26/18
STFL
03/26/18
UPGRADE
STFL
Buy
Aratana Therapeutics upgraded to Buy from Hold at Stifel
03/27/18
03/27/18
UPGRADE
Target $8

Buy
Aratana Therapeutics upgraded on Entyce traction, M&A potential at Stifel
As previously reported, Stifel analyst Jonathan Block upgraded Aratana Therapeutics (PETX) to Buy from Hold. The early traction for Entyce, which was launched October 2017, has increased his conviction that the drug will act as the main revenue driver for Aratana in coming years, Block tells investors. Additionally, he argues that Aratana's portfolio may be appealing to a big animal health company, with Lilly's (LLY) Elanco viewed by Block as the most obvious candidate. The analyst raised his price target on Aratana shares to $8 from $6.
03/27/18
03/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. BB&T (BBT) upgraded to Buy from Neutral at B. Riley FBR and to Outperform from Market Perform at Wells Fargo. 2. Aratana Therapeutics (PETX) upgraded to Buy from Hold at Stifel with analyst Jonathan Block saying the early traction for Entyce, which was launched October 2017, has increased his conviction that the drug will act as the main revenue driver for Aratana in coming years. 3. Prologis (PLD) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Mueller saying he is shuffling his ratings in the REIT space following GGP's (GGP) takeout by Brookfield Property Partners (BPY). 4. Brookfield Property (BPY) upgraded to Buy from Hold at Canaccord. 5. Roku (ROKU) upgraded to Neutral from Sell at Citi with analyst Mark May citing valuation for the upgrade following the stock's recent underperformance, but admits the upcoming lock-up expiration could serve as a negative catalyst. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/11/19
STFL
01/11/19
DOWNGRADE
Target $5
STFL
Hold
Aratana Therapeutics downgraded to Hold from Buy at Stifel
Stifel analyst Jonathan Block downgraded Aratana Therapeutics to Hold and lowered his price target for the shares to $5 from $8. While the company is seeing ongoing Entyce adoption, little progress has been made on lengthening the drug's duration, Block tells investors in a research note. He lowered his 2019-2024 Entyce estimates "materially," and when coupled with a "modest" pipeline, recent COO departure and a key shareholder reducing its position, the analyst is moving to the sidelines.
TRUP Trupanion
$28.11

0.22 (0.79%)

10/02/18
KING
10/02/18
UPGRADE
Target $36
KING
Buy
Trupanion upgraded to Buy from Neutral at CL King
CL King analyst David Westenberg upgraded Trupanion to Buy from Neutral with a $36 price target saying the "short" reports have flaws and provide an attractive entry point.
09/06/18
RAJA
09/06/18
INITIATION
Target $46
RAJA
Outperform
Trupanion initiated with an Outperform at Raymond James
Raymond James initiated Trupanion with an Outperform and $46 price target.
08/03/18
LSCM
08/03/18
NO CHANGE
Target $46
LSCM
Buy
Trupanion price target raised to $46 from $41 at Lake Street
Lake Street analyst Mark Argento raised his price target for Trupanion to $46 saying the company's "solid" quarter shows it continues to execute. Trupanion is growing its enrolled pets with attractive economics while leveraging its technology platform to enable more Trupanion Express direct pay hospital partner, Argento tells investors in a post-earnings research note. The analyst continues to believe Trupanion's value proposition to both the consumer and the veterinarian remains strong. He reiterates a Buy rating on the shares.
08/03/18
COWN
08/03/18
NO CHANGE
Target $47
COWN
Outperform
Trupanion price target raised to $47 from $41 at Cowen
Cowen analyst Thomas Champion raised his price target on Trupanion to $47 from $41 following positive Q2 results. The analyst said pet additions were strong, suggesting ramping growth initiatives and rising efficiency. Champion reiterated his Outperform rating on Trupanion shares.
ZTS Zoetis
$84.62

0.4 (0.47%)

10/15/18
JPMS
10/15/18
UPGRADE
Target $100
JPMS
Overweight
Zoetis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Christopher Schott upgraded Zoetis to Overweight and raised his price target for the shares to $100 from $84. The company's above market growth looks "highly sustainable," Schott tells investors in a research note.
10/17/18
CANT
10/17/18
NO CHANGE
Target $105
CANT
Overweight
Zoetis price target raised to $105 from $98 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target on shares of Zoetis to $105 from $98 and maintains an Overweight rating on the stock, telling investors that the "ride keeps getting better."
11/12/18
BMOC
11/12/18
NO CHANGE
Target $93
BMOC
Market Perform
Zoetis price target raised to $93 from $86 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Zoetis to $93 after its Q3 earnings beat and raised FY18 guidance. The analyst acknowledges that the company's "commercial and R&D execution have been excellent", leading to its premium valuation. Arfaei keeps his Market Perform on Zoetis however, noting that in spite of its performance amid the reasonably high expectations, the company's insufficient pipeline visibility and premium valuation warrant a neutral stance.
12/19/18
BMOC
12/19/18
NO CHANGE
Target $32
BMOC
Market Perform
Elanco price target lowered to $32 from $37 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Elanco (ELAN) to $32 and kept his Market Perform rating, saying its FY19 guidance was "modestly below" his expectations and that he doubts that the management is being conservative. The analyst also cites "significant uncertainties" in 2020 related to competitor's products and the company's R&D productivity, also lowering his FY19 EPS view to $1.13 from $1.22. Arfaei believes that the market valuation on Elanco similar to Zoetis (ZTS) is "premature" based on the "important differences in revenue growth potential, product mix, and execution track record" of the two companies.

TODAY'S FREE FLY STORIES

21:25
03/25/19
03/25
21:25
03/25/19
21:25
General news
Fed's Rosengren warned that U.S. Q1 growth is likely to be weak »

Fed's Rosengren…

BBBY

Bed Bath & Beyond

$13.87

0.17 (1.24%)

20:44
03/25/19
03/25
20:44
03/25/19
20:44
Periodicals
Activist firms seek to replace Bed Bath & Beyond board, CEO, WSJ says »

Activist funds -Legion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

RTN

Raytheon

$180.58

-0.82 (-0.45%)

, BA

Boeing

$370.52

8.37 (2.31%)

20:36
03/25/19
03/25
20:36
03/25/19
20:36
Hot Stocks
Raytheon kill vehicle hits ICBM target in first dual-salvo test »

For the first time, the…

RTN

Raytheon

$180.58

-0.82 (-0.45%)

BA

Boeing

$370.52

8.37 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

20:35
03/25/19
03/25
20:35
03/25/19
20:35
General news
The "Summary of Opinions" from the BoJ's March meeting »

The "Summary of…

WHD

Cactus

$36.03

1.225 (3.52%)

20:27
03/25/19
03/25
20:27
03/25/19
20:27
Hot Stocks
Cactus VP of Operations sells 229K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$56.67

-0.065 (-0.11%)

, MKC

McCormick

$143.88

1.58 (1.11%)

20:25
03/25/19
03/25
20:25
03/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.67

-0.065 (-0.11%)

MKC

McCormick

$143.88

1.58 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

CRTO

Criteo

$21.99

-3.4 (-13.39%)

20:19
03/25/19
03/25
20:19
03/25/19
20:19
Downgrade
Criteo rating change at KeyBanc »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

20:02
03/25/19
03/25
20:02
03/25/19
20:02
Periodicals
Samsung sees weaker environment for display, memory in Q1, Bloomberg says »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$370.52

8.37 (2.31%)

19:51
03/25/19
03/25
19:51
03/25/19
19:51
Hot Stocks
U.S. MDA and Boeing Complete Historic Missile Defense Test »

The U.S. Missile Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MCD

McDonald's

$185.66

-1.11 (-0.59%)

19:49
03/25/19
03/25
19:49
03/25/19
19:49
Periodicals
McDonald's purchase price of Dynamic Yield above $300M, Bloomberg says »

The purchase of Dynamic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

SSNLF

Samsung

$0.00

(0.00%)

19:32
03/25/19
03/25
19:32
03/25/19
19:32
Periodicals
Breaking Periodicals news story on Samsung »

Samsung sees Q1 below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWR

American States Water

$71.51

0.505 (0.71%)

19:22
03/25/19
03/25
19:22
03/25/19
19:22
Hot Stocks
American States Water CEO sells 12.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$56.35

-1.38 (-2.39%)

19:10
03/25/19
03/25
19:10
03/25/19
19:10
Hot Stocks
Methanex confirms receipt of director nominees notice from M&G »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

, SAEX

SAExploration

$4.03

0.13 (3.33%)

18:55
03/25/19
03/25
18:55
03/25/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

SAEX

SAExploration

$4.03

0.13 (3.33%)

IQ

iQIYI

$24.01

-0.86 (-3.46%)

MYOK

MyoKardia

$51.87

-2.44 (-4.49%)

CTMX

CytomX Therapeutics

$10.76

0.33 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 21

    May

  • 27

    Mar

HPQ

HP Inc.

$18.97

-0.4 (-2.07%)

18:48
03/25/19
03/25
18:48
03/25/19
18:48
Periodicals
HP lawyer tells court Autonomy's Lynch inflated sales data, Reuters says »

A lawyer for HP told a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

PEGA

Pegasystems

$63.61

-0.27 (-0.42%)

18:45
03/25/19
03/25
18:45
03/25/19
18:45
Hot Stocks
Pegasystems CEO: We are massively changing our marketing strategy »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SMTC

Semtech

$52.59

-0.38 (-0.72%)

18:32
03/25/19
03/25
18:32
03/25/19
18:32
Hot Stocks
Semtech CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TMO

Thermo Fisher

$268.89

5.015 (1.90%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Hot Stocks
Thermo Fisher CEO: We have a very disciplined M&A process »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Periodicals
Parliament forces votes on Brexit plan options, Bloomberg reports »

Lawmakers of U.K.…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.99

-0.56 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$185.66

-1.11 (-0.59%)

18:23
03/25/19
03/25
18:23
03/25/19
18:23
Hot Stocks
McDonald's to acquire Dynamic Yield, terms not stated »

McDonald's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

BA

Boeing

$370.52

8.37 (2.31%)

18:22
03/25/19
03/25
18:22
03/25/19
18:22
Periodicals
Boeing software fix to prevent repeated activiation of MCAS, Reuters says »

A Boeing software repair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ACHC

Acadia

$29.47

-0.59 (-1.96%)

17:58
03/25/19
03/25
17:58
03/25/19
17:58
Hot Stocks
Acadia says President Brett Turner leaving by mutual agreement »

Brent Turner, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.78

-2.33 (-1.22%)

17:41
03/25/19
03/25
17:41
03/25/19
17:41
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

ZFGN

Zafgen

$2.70

-0.15 (-5.26%)

17:38
03/25/19
03/25
17:38
03/25/19
17:38
Hot Stocks
Armistice Capital reports 5.6% passive stake in Zafgen »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$268.56

0.27 (0.10%)

17:36
03/25/19
03/25
17:36
03/25/19
17:36
Hot Stocks
Northrop Grumman awarded $245.05M Navy contract modification »

Northrop Grumman has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.